Updated Treatment Algorithm of Pulmonary Arterial Hypertension

被引:517
作者
Galie, Nazzareno [1 ]
Corris, Paul A. [2 ,3 ]
Frost, Adaani [4 ]
Girgis, Reda E. [5 ]
Granton, John [6 ]
Jing, Zhi Cheng [7 ,8 ,9 ]
Klepetko, Walter [10 ]
McGoon, Michael D. [11 ]
McLaughlin, Vallerie V. [12 ]
Preston, Ioana R. [13 ]
Rubin, Lewis J. [14 ]
Sandoval, Julio [15 ]
Seeger, Werner [16 ]
Keogh, Anne [17 ]
机构
[1] Bologna Univ Hosp, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy
[2] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA
[6] Univ Toronto, Div Respirol, Toronto, ON, Canada
[7] Peking Union Med Coll, Fu Wai Hosp, Beijing 100021, Peoples R China
[8] Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Beijing 100021, Peoples R China
[9] Chinese Acad Med Sci, Beijing 100730, Peoples R China
[10] Med Univ Vienna, Vienna Gen Hosp, Dept Thorac Surg, Vienna, Austria
[11] Mayo Clin, Rochester, MN USA
[12] Univ Michigan, Ann Arbor, MI 48109 USA
[13] Tufts Univ, Sch Med, Tufts Med Ctr, Pulm Crit Care & Sleep Div, Boston, MA 02111 USA
[14] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[15] Natl Inst Cardiol Mexico, Mexico City, DF, Mexico
[16] Univ Giessen & Marburg Lung Ctr, Max Planck Inst Heart & Lung Res, Giessen, Germany
[17] St Vincents Hosp, Heart Transplant Unit, Sydney, NSW 2010, Australia
关键词
endothelin receptor antagonists; guanylate cyclase stimulators; hypertension; pulmonary; lung transplantation; phosphodiesterase type-5 inhibitors; prostanoids; CONTINUOUS INTRAVENOUS EPOPROSTENOL; HEART-LUNG TRANSPLANTATION; SURROGATE END-POINTS; QUALITY-OF-LIFE; DOUBLE-BLIND; COMBINATION THERAPY; INHALED ILOPROST; INTERNATIONAL-SOCIETY; EISENMENGER-SYNDROME; AMBRISENTAN THERAPY;
D O I
10.1016/j.jacc.2013.10.031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple and in some ways conflicting. The treatment algorithm usually includes different types of recommendations with varying degrees of scientific evidence. In addition, the algorithm is required to be comprehensive but not too complex, informative yet simple and straightforward. The type of information in the treatment algorithm are heterogeneous including clinical, hemodynamic, medical, interventional, pharmacological and regulatory recommendations. Stakeholders (or users) including physicians from various specialties and with variable expertise in PAH, nurses, patients and patients' associations, healthcare providers, regulatory agencies and industry are often interested in the PAH treatment algorithm for different reasons. These are the considerable challenges faced when proposing appropriate updates to the current evidence-based treatment algorithm. The current treatment algorithm may be divided into 3 main areas: 1) general measures, supportive therapy, referral strategy, acute vasoreactivity testing and chronic treatment with calcium channel blockers; 2) initial therapy with approved PAH drugs; and 3) clinical response to the initial therapy, combination therapy, balloon atrial septostomy, and lung transplantation. All three sections will be revisited highlighting information newly available in the past 5 years and proposing updates where appropriate. The European Society of Cardiology grades of recommendation and levels of evidence will be adopted to rank the proposed treatments. (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:D60 / D72
页数:13
相关论文
共 86 条
[51]   Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension A Randomized, Controlled Trial [J].
Jing, Zhi-Cheng ;
Parikh, Keyur ;
Pulido, Tomas ;
Jerjes-Sanchez, Carlos ;
White, R. James ;
Allen, Roblee ;
Torbicki, Adam ;
Xu, Kai-Feng ;
Yehle, David ;
Laliberte, Kevin ;
Arneson, Carl ;
Rubin, Lewis J. .
CIRCULATION, 2013, 127 (05) :624-633
[52]   Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study [J].
Jing, Zhi-Cheng ;
Yu, Zai-Xin ;
Shen, Jie-Yan ;
Wu, Bing-Xiang ;
Xu, Kai-Feng ;
Zhu, Xian-Yang ;
Pan, Lei ;
Zhang, Zhuo-Li ;
Liu, Xue-Qin ;
Zhang, Yu-Shun ;
Jiang, Xin ;
Galie, Nazzareno .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (12) :1723-1729
[53]  
JONES DA, 1995, MOL PHARMACOL, V48, P890
[54]   Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study [J].
Kemp, Kristina ;
Savale, Laurent ;
O'Callaghan, Dermot S. ;
Jais, Xavier ;
Montani, David ;
Humbert, Marc ;
Simonneau, Gerald ;
Sitbon, Olivier .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (02) :150-158
[55]   Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension [J].
Keogh, Anne M. ;
Mayer, Eckhard ;
Benza, Raymond L. ;
Corris, Paul ;
Dartevelle, Philippe G. ;
Frost, Adaani E. ;
Kim, Nick H. ;
Lang, Irene M. ;
Pepke-Zaba, Joanna ;
Sandoval, Julio .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (01) :S67-S77
[56]   Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension [J].
Kurzyna, Marcin ;
Dabrowski, Marek ;
Bielecki, Dariusz ;
Fijalkowska, Anna ;
Pruszczyk, Piotr ;
Opolski, Grzegorz ;
Burakowski, Janusz ;
Florczyk, Michal ;
Tomkowski, Witold Z. ;
Wawrzynska, Liliana ;
Szturmowicz, Monika ;
Torbicki, Adam .
CHEST, 2007, 131 (04) :977-983
[57]   Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities [J].
McGoon, Michael D. ;
Frost, Adaani E. ;
Oudiz, Ronald J. ;
Badesch, David B. ;
Galie, Nazzareno ;
Olschewski, Horst ;
McLaughlin, Vallerie V. ;
Gerber, Michael J. ;
Dufton, Chris ;
Despain, Darrin J. ;
Rubin, Lewis J. .
CHEST, 2009, 135 (01) :122-129
[58]   Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension [J].
McLaughlin, Vallerie V. ;
Oucliz, Ronald J. ;
Frost, Aclaani ;
Tapson, Victor F. ;
Murali, Srinivas ;
Channick, Richard N. ;
Badesch, David B. ;
Barst, Robyn J. ;
Hsu, Henry H. ;
Rubin, Lewis J. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (11) :1257-1263
[59]   Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial [J].
McLaughlin, Vallerie V. ;
Benza, Raymond L. ;
Rubin, Lewis J. ;
Channick, Richard N. ;
Voswinckel, Robert ;
Tapson, Victor F. ;
Robbins, Ivan M. ;
Olschewski, Horst ;
Rubenfire, Melvyn ;
Seeger, Werner .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (18) :1915-1922
[60]   Survival in primary pulmonary hypertension - The impact of epoprostenol therapy [J].
McLaughlin, VV ;
Shillington, A ;
Rich, S .
CIRCULATION, 2002, 106 (12) :1477-1482